Ask AI · How Geopolitical Risks Affect WuXi AppTec’s Dependence on the U.S. Market?

Author: Sun Ningyu

Source: Global Finance Talk

On the evening of March 23, the industry leader in the CXO sector, WuXi AppTec, officially released its annual report for 2025, presenting a performance sheet with steady revenue growth and a doubling of net profit, attracting attention.

Net Profit Doubles

In 2025, WuXi AppTec achieved operating revenue of 45.456 billion yuan, a year-on-year increase of 15.84%; net profit attributable to shareholders of the listed company reached 19.151 billion yuan, a significant year-on-year growth of 102.65%, with basic earnings per share of 6.70 yuan, and the net profit growth rate reaching a nearly five-year high.

In terms of cash flow, WuXi AppTec’s net cash flow generated from operating activities in 2025 reached 17.203 billion yuan, a year-on-year increase of 38.66%, significantly outperforming the revenue growth rate, demonstrating strong cash-generating ability from its core business.

At the same time, WuXi AppTec launched a substantial cash dividend plan, proposing to distribute a cash dividend of 15.79 yuan (tax included) for every 10 shares to all shareholders, which, based on the total share capital as of the announcement date, amounts to approximately 4.712 billion yuan in cash dividends. In addition to the previously implemented interim dividend and special dividend, the total cash dividend for 2025 reached 6.755 billion yuan, accounting for 45.72% of the year’s net profit, continuously fulfilling the commitment to return to shareholders.

From a business structure perspective, the chemistry sector remains WuXi AppTec’s core growth engine, achieving segment revenue of 36.466 billion yuan in 2025, a year-on-year increase of 25.52%, accounting for over 80% of total revenue. Among these, the TIDES business (oligonucleotides and peptides) generated revenue of 11.37 billion yuan, a year-on-year surge of 96.0%, becoming a key highlight driving the annual performance; the small molecule CDMO business generated revenue of 19.92 billion yuan, a year-on-year increase of 11.4%.

Additionally, the testing business achieved operating revenue of 4.042 billion yuan, a year-on-year increase of 4.69%; the biology business achieved operating revenue of 2.677 billion yuan, a year-on-year increase of 5.24%, both sectors experiencing restorative positive growth.

Regarding order reserves, as of the end of 2025, WuXi AppTec had approximately 58 billion yuan in ongoing business orders, a year-on-year increase of 28.8%, providing solid support for the stable growth of future performance.

Breaking down the performance growth of WuXi AppTec in 2025, the core driving force comes from the steady improvement in the profitability of its main business and the substantial contribution from non-recurring gains, both of which jointly propelled the doubling of net profit.

From the core main business perspective, the net profit attributable to parent company after excluding non-recurring gains was 13.241 billion yuan, a year-on-year increase of 32.56%, with the growth rate significantly higher than the revenue growth rate, primarily due to optimization of product structure and effective cost control.

In 2025, the overall gross profit margin of the company reached 47.64%, a year-on-year increase of 6.16 percentage points, with the gross profit margin of the chemistry business seeing the most significant improvement, mainly benefiting from the increasing proportion of high value-added projects in late-stage clinical and commercialization, as well as the enhancement of production efficiency brought about by process optimization.

Strong Customer Stickiness

From WuXi AppTec’s current operational status, the company still maintains a global leading advantage in the integrated CXO platform, having built a service capability covering the entire process of “drug discovery - R&D - production.” With over 40,000 employees worldwide, more than 75% of whom are R&D personnel, it serves 19 of the top 20 pharmaceutical companies globally, placing customer stickiness and globalization service capabilities at an industry-leading level.

In terms of capacity layout, WuXi AppTec continues to advance global capacity construction, with the domestic peptide production base in Taixing completing construction ahead of schedule. The total volume of peptide solid-phase synthesis reactors has surpassed 100,000 liters, making it the largest in the world.

Overseas R&D and production bases in Singapore and Delaware, USA, are also steadily advancing, further improving the global supply chain layout.

From the actual implementation of products and services, the advantages of WuXi AppTec’s “end-to-end” CRDMO integrated model continue to stand out, enabling full lifecycle value capture from early drug discovery to commercial production.

In the small molecule field, WuXi AppTec added a total of 839 new molecules to its pipeline in 2025, with 22 new commercial and Phase III clinical projects added throughout the year. Among the 30 small molecule new drugs approved by the FDA in the United States in 2025, 8 were serviced by the company, continuously solidifying its global market share. In the TIDES field, the company has deeply partnered with giants in the GLP-1 field, such as Eli Lilly and Novo Nordisk, with the number of related pipelines increasing to 26, of which 17 have entered Phase II/III clinical trials, becoming the company’s clear second growth curve.

In terms of customer structure, in 2025, revenue from U.S. clients in WuXi AppTec’s ongoing business reached 31.25 billion yuan, a year-on-year increase of 34.3%, accounting for over 70% of ongoing revenue and still being the company’s most core revenue source; revenue from customers in Europe, China, and other regions showed varying degrees of decline, reflecting that the company’s customer structure remains relatively concentrated, with a relatively high dependence on the U.S. market.

As a leading enterprise in the global CXO sector, WuXi AppTec’s core investment value lies in its unique integrated CRDMO platform that covers the entire drug development process, a core barrier that most segmented CXO companies cannot match.

From the essence of the industry, the CXO sector is a technology and capital-intensive industry. After over twenty years of accumulation, WuXi AppTec has established a scale effect and technological barrier that are difficult to replicate. The company possesses the world’s largest scale of chemical synthesis capability, with an annual synthesis of over 500,000 compounds. This scale effect significantly reduces the unit R&D and production costs, making it challenging for new entrants to catch up in the short term.

Additionally, the extremely high customer switching costs constitute another core moat for the company. WuXi AppTec’s collaborations with large pharmaceutical companies are often comprehensive and deep, starting from the early drug discovery stage and extending to the commercial production phase. For pharmaceutical companies, changing CXO partners means significant time costs and compliance risks; therefore, customer stickiness is strong. Data shows that in 2025, the average cooperation duration with the company’s top ten customers exceeded 12 years.

From the industry development trend, the global CXO industry is still in a steady growth phase in a long cycle.

It is predicted that by 2025, the global pharmaceutical CXO market size will reach $196.6 billion, with a compound annual growth rate of 14.0% from 2021 to 2025. Among these, the growth rate of the Chinese CXO market significantly leads globally, with an expected market size of 247.7 billion yuan in 2025 and a compound annual growth rate of 26.56% from 2020 to 2025.

The core logic of industry growth comes from the steady increase in R&D investment by global innovative pharmaceutical companies, the continuous deepening of R&D outsourcing penetration, and structural opportunities arising from the research and development boom of new molecular types of drugs such as ADCs, peptides, and oligonucleotides.

For WuXi AppTec, future market opportunities mainly come from three core directions: First, explosive growth in new molecular businesses such as TIDES, as the demand for related CDMO services rapidly expands with the ongoing heat in the GLP-1 and small nucleic acid drug sectors, the company, leveraging its global leading capacity and technological advantages, is expected to continue capturing market share.

Second, the incremental opportunities brought by the wave of domestic innovative drugs going abroad, with the number and value of overseas licensing transactions for Chinese innovative drugs continuing to rise in 2025, domestic pharmaceutical companies have significantly increased their demand for CXO services with global delivery capabilities, and the company, as a domestic leader, is expected to benefit fully.

Third, the technical dividends of AI + drug development, as the company has deeply integrated AI technology into all business segments such as drug discovery and process optimization, significantly shortening R&D cycles and reducing R&D costs, further consolidating technological barriers and cost advantages.

Penetrating the Doubling Growth Surface

Despite WuXi AppTec delivering a remarkable performance sheet with a doubling of net profit, there remains widespread skepticism in the market regarding the sustainability of its high growth; the company’s future development still faces multiple risk factors that cannot be ignored.

First, the geopolitical risks looming overhead represent the greatest uncertainty constraining the company’s valuation and long-term development. In December 2025, the revised “Biodefense Act” officially came into effect as part of the “2026 National Defense Authorization Act.” Although it did not directly name WuXi AppTec or limit commercial orders from private pharmaceutical companies, it set a transition period. However, the act explicitly prohibits U.S. federal agencies from using funds to procure services from “biotechnology companies of concern,” and the U.S. Congress continues to urge the inclusion of WuXi AppTec on the “companies of concern” list.

In February 2026, the Pentagon briefly listed WuXi AppTec as one of the 1260H military-related enterprises, but it was quickly withdrawn, highlighting the policy’s volatility and uncertainty. With nearly 70% of the company’s revenue derived from the U.S. market, further tightening of policies in the future could lead to the loss of core customer orders, substantially impacting performance.

Second, the doubling of net profit is significantly influenced by one-time gains, raising questions about the quality of growth.

In 2025, WuXi AppTec sold part of its stake in the joint venture WuXi XDC and divested part of its clinical business, with net gains from some of the shares estimated at approximately 4.161 billion yuan, as well as net gains of about 1.434 billion yuan from the sale of 100% equity of Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd.

Excluding this portion of one-time gains, although the company’s net profit growth excluding non-recurring items could still exceed 30%, it remains a significant gap from the 102.65% net profit growth rate. Such high growth reliant on asset disposals lacks sustainability; if the company loses the support of investment income in 2026, its net profit growth is highly likely to experience a significant decline.

Moreover, WuXi AppTec faces multiple risks including customer concentration, intensified industry competition, and capacity expansion.

The sales from WuXi AppTec’s top five customers account for nearly 50% of total sales. If core major customers reduce R&D investment or shift orders, it will directly impact the stability of the company’s revenue.

The domestic CXO industry, after experiencing capacity expansion during the pandemic, currently has overall capacity at a high level, and the competition among leading enterprises in hot tracks like TIDES is becoming increasingly fierce, which may pressure gross profit margins.

WuXi AppTec’s prior large-scale capacity expansion may lead to increased depreciation costs if future industry demand fails to meet expectations, resulting in lower capacity utilization and dragging down profit performance.

Finally, if the global financing environment for innovative drugs tightens, pharmaceutical companies will generally cut R&D investments. As a “water supplier” in the innovative drug industry chain, the demand for the CXO sector will also be directly impacted, and the company’s performance growth will face downward pressure.

In summary, WuXi AppTec’s 2025 performance reflects both the endogenous growth momentum brought by its integrated platform and the short-term profit enhancement from asset disposals.

For investors, it is essential to look beyond the shiny surface of the 102.65% doubling of net profit and see the true quality and underlying logic of performance growth.

In this doubling performance sheet, over half of the profit increment comes from one-time non-recurring gains from asset disposals. After excluding this impact, the company’s net profit growth excluding non-recurring items is only 32.56%, revealing a substantial gap with the apparent growth rate. This high growth reliant on asset disposals is not sustainable.

At the same time, it is important to recognize the structural concerns behind the impressive numbers: over 70% of revenue depends on geopolitical risks in the U.S. market, operational shortfalls due to weak growth in non-core businesses, and the risk of gross profit margins being pressured by intensified competition in hot sectors.

Investors must disregard the noise of short-term profit fluctuations and rationally assess the company’s sustained growth capability, risk hedging ability, and long-term moat to make informed investment decisions.

Reader Advisory: This article is based on publicly available information or content provided by interviewees. Global Finance Talk and the author of the article do not guarantee the completeness and accuracy of the related information. Under no circumstances does the content of this article constitute investment advice. The market carries risks; investments should be made cautiously! Unauthorized reproduction or plagiarism is prohibited!